Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Tessera Therapeutics, founded in 2018 and headquartered in Cambridge, Massachusetts, is a pioneering biotechnology company focused on genetic medicine. Their primary service, Gene Writing, is a novel genome engineering technology that aims to treat diseases at their source by writing therapeutic messages into the genome. This innovative approach has positioned Tessera as a potential leader in the healthcare and medical research sectors.
Since its inception, Tessera Therapeutics has demonstrated significant growth and attracted substantial investor interest. The company has successfully raised $530 million across multiple funding rounds, with its most recent Series C round in April 2022 securing $300 million. This latest funding round valued the company at approximately $1.69 billion, highlighting the strong confidence investors have in Tessera's potential.
As of now, there is no concrete information available regarding Tessera Therapeutics' plans for an initial public offering (IPO). The company has not made any official announcements or filed any public documents indicating its intention to go public. Without specific news or reports about the company's IPO prospects, it would be premature to speculate on the likelihood or timing of such an event.
Several factors could influence Tessera Therapeutics' decision to pursue an IPO in the future. These may include the company's financial performance, market conditions in the biotechnology sector, the progress of its Gene Writing technology, and the overall state of the IPO market. Additionally, the company's ability to secure partnerships or achieve significant milestones in its research and development efforts could play a role in any future IPO considerations.
Investors interested in Tessera Therapeutics should continue to monitor the company's progress and any official announcements regarding its future plans. As with any private company, opportunities to invest in Tessera Therapeutics stock are currently limited to private funding rounds and are not available to the general public.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Tessera Therapeutics' IPO prospects remain uncertain, investors eager to explore opportunities in the innovative gene writing technology space don't have to wait. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides the opportunity to invest in potential leaders in the biotechnology sector, like Tessera Therapeutics, with lower minimum investments than traditional private equity opportunities. This allows you to potentially benefit from the growth of cutting-edge companies shaping the future of gene therapy and precision medicine.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
